{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:56:30Z","timestamp":1790398590884,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.smim.2014.01.009","type":"journal-article","created":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T04:45:29Z","timestamp":1393649129000},"page":"88-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"title":["A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy"],"prefix":"10.1016","volume":"26","author":[{"given":"Toshio","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Narazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamitsu","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2014.01.009_bib0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.smim.2014.01.009_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","article-title":"The biology of interleukin-6","volume":"74","author":"Kishimoto","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.smim.2014.01.009_bib0015","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1073\/pnas.86.19.7547","article-title":"IgG1 plasmacytosis in interleukin 6 transgenic mice","volume":"86","author":"Suematsu","year":"1989","journal-title":"Proc Acad Natl Sci U S A"},{"key":"10.1016\/j.smim.2014.01.009_bib0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.smim.2014.01.009_bib0025","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2014.01.009_bib0030","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.smim.2014.01.009_bib0040","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0045","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1002\/art.24126","article-title":"Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses","volume":"58","author":"Fujimoto","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2014.01.009_bib0050","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1073\/pnas.0802218105","article-title":"IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis","volume":"105","author":"Serada","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2014.01.009_bib0055","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1167\/iovs.10-6272","article-title":"Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis","volume":"52","author":"Haruta","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.smim.2014.01.009_bib0060","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.20120994","article-title":"The origins, function, and regulation of T follicular helper cells","volume":"209","author":"Ma","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.smim.2014.01.009_bib0065","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.141.5.1543","article-title":"IL-6\/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells","volume":"141","author":"Okada","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0070","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/bj2650621","article-title":"Interleukin-6 and the acute phase response","volume":"265","author":"Heinrich","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/j.smim.2014.01.009_bib0075","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.smim.2014.01.009_bib0080","series-title":"Amyloidosis \u2013 An Insight to Disease of Systems and Novel Therapies","first-page":"155","article-title":"Tocilizumab for the treatment of AA amyloidosis","author":"Tanaka","year":"2011"},{"key":"10.1016\/j.smim.2014.01.009_bib0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","article-title":"Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein","volume":"358","author":"Gillmore","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2014.01.009_bib0090","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.smim.2014.01.009_bib0095","doi-asserted-by":"crossref","first-page":"6843","DOI":"10.1073\/pnas.0502257102","article-title":"Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response","volume":"102","author":"Liuzzi","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2014.01.009_bib0100","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0167-5699(90)90173-7","article-title":"Biological and clinical aspects of interleukin 6","volume":"11","author":"Hirano","year":"1990","journal-title":"Immunol Today"},{"key":"10.1016\/j.smim.2014.01.009_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60532-5","article-title":"Interleukin-6 in biology and medicine","volume":"54","author":"Akira","year":"1993","journal-title":"Adv Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0110","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","article-title":"IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17","volume":"47","author":"Hashizume","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2014.01.009_bib0115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jbmr.5650110113","article-title":"Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation","volume":"11","author":"Kotake","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.smim.2014.01.009_bib0120","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.11143","article-title":"Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis","volume":"48","author":"Nakahara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2014.01.009_bib0125","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes","volume":"86","author":"Grossman","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2014.01.009_bib0130","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1523-1747.ep12483971","article-title":"Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6","volume":"97","author":"Duncan","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.smim.2014.01.009_bib0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1126\/science.1411569","article-title":"Interleukin-6 and its receptor: a paradigm for cytokines","volume":"258","author":"Kishimoto","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.smim.2014.01.009_bib0140","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.3136546","article-title":"Cloning and expression of the human interleukin-6 (BSF-2\/IFN beta 2) receptor","volume":"241","author":"Yamasaki","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.smim.2014.01.009_bib0145","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","article-title":"Molecular cloning and expression of an IL-6 signal transducer, gp130","volume":"63","author":"Hibi","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.smim.2014.01.009_bib0150","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.V82.4.1120.1120","article-title":"Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130","volume":"82","author":"Narazaki","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.smim.2014.01.009_bib0155","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1146\/annurev.immunol.15.1.797","article-title":"Gp130 and the interleukin-6 family of cytokines","volume":"15","author":"Taga","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0160","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1126\/science.8511589","article-title":"IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase","volume":"260","author":"Murakami","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.smim.2014.01.009_bib0165","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"21","author":"Jones","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.smim.2014.01.009_bib0170","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the proinflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.smim.2014.01.009_bib0175","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1126\/science.1083901","article-title":"Hexameric structure and assembly of the interleukin-6\/IL-6 alpha-receptor\/gp130 complex","volume":"300","author":"Boulanger","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.smim.2014.01.009_bib0180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0092-8674(94)90333-6","article-title":"Cytokine signal transduction","volume":"76","author":"Kishimoto","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.smim.2014.01.009_bib0185","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/43219","article-title":"Structure and function of a new STAT-induced STAT inhibitor","volume":"387","author":"Naka","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.smim.2014.01.009_bib0190","doi-asserted-by":"crossref","first-page":"12848","DOI":"10.1074\/jbc.275.17.12848","article-title":"SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment sites of gp130","volume":"275","author":"Schmitz","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.smim.2014.01.009_bib0195","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08830185.2010.529976","article-title":"Pathogen recognition by the innate immune system","volume":"30","author":"Kumar","year":"2011","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.0306164","article-title":"DAMPs, PAMPs and alarmins: all we need to know about danger","volume":"81","author":"Bianchi","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.smim.2014.01.009_bib0205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2492\/inflammregen.33.054","article-title":"Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases","volume":"33","author":"Tanaka","year":"2013","journal-title":"Inflamm Regeneration"},{"key":"10.1016\/j.smim.2014.01.009_bib0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1600-065X.1992.tb01407.x","article-title":"IL-6 and NF-IL6 in acute-phase response and viral infection","volume":"127","author":"Akira","year":"1992","journal-title":"Immunol Rev"},{"key":"10.1016\/j.smim.2014.01.009_bib0215","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ni1584","article-title":"Post-transcriptional control of cytokine production","volume":"9","author":"Anderson","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0220","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0968-0004(00)89102-1","article-title":"AU-rich elements: characterization and importance in mRNA degradation","volume":"20","author":"Chen","year":"1995","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.smim.2014.01.009_bib0225","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/nature07924","article-title":"Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay","volume":"458","author":"Matsushita","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.smim.2014.01.009_bib0230","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/ni.2137","article-title":"The IkappaB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1","volume":"12","author":"Iwasaki","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0235","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1073\/pnas.1307419110","article-title":"Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo","volume":"110","author":"Masuda","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2014.01.009_bib0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.84.1.228","article-title":"Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production","volume":"84","author":"Hirano","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2014.01.009_bib0245","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/eji.1830181122","article-title":"Excessive production of interleukin 6\/B cell stimulatory factor-2 in rheumatoid arthritis","volume":"18","author":"Hirano","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0250","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman's disease","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.smim.2014.01.009_bib0255","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1006\/cyto.2002.2012","article-title":"Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice","volume":"20","author":"Katsume","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.smim.2014.01.009_bib0260","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.187.4.461","article-title":"Interleukin 6 is required for the development of collagen-induced arthritis","volume":"187","author":"Alonzi","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.smim.2014.01.009_bib0265","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1073\/pnas.95.14.8222","article-title":"Interleukin 6 plays a key role in the development of antigen-induced arthritis","volume":"95","author":"Ohshima","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2014.01.009_bib0270","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2249.1998.00612.x","article-title":"IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB\/W F1 mice","volume":"112","author":"Mihara","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0275","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1002\/art.30539","article-title":"Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling","volume":"63","author":"Yoshizaki","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2014.01.009_bib0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","article-title":"Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma","volume":"180","author":"Kitaba","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.smim.2014.01.009_bib0285","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/art.24689","article-title":"Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A","volume":"60","author":"Okiyama","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2014.01.009_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"Interleukin-6: from basic science to medicine \u2013 40 years in immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0295","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-pharmtox-010611-134715","article-title":"Therapeutic targeting of the interleukin-6 receptor","volume":"52","author":"Tanaka","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.smim.2014.01.009_bib0300","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2014.01.009_bib0305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4137\/CMT.S9282","article-title":"Tocilizumab: an updated review of its use in the treatment of rheumatoid arthritis and its application for other immune-mediated diseases","volume":"5","author":"Tanaka","year":"2013","journal-title":"Clin Med Insights Ther"},{"key":"10.1016\/j.smim.2014.01.009_bib0310","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2014.01.009_bib0315","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2014.01.009_bib0320","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V95.1.56","article-title":"Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy","volume":"95","author":"Nishimoto","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.smim.2014.01.009_bib0325","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.smim.2014.01.009_bib0330","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"Mclnnes","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2014.01.009_bib0335","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/CMAMD.S7371","article-title":"Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis","volume":"5","author":"Ogata","year":"2012","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"10.1016\/j.smim.2014.01.009_bib0340","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomized controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2014.01.009_bib0345","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/s10165-008-0125-1","volume":"19","author":"Nishimoto","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.smim.2014.01.009_bib0350","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2011-201282","article-title":"Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)","volume":"72","author":"Dougados","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2014.01.009_bib0355","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2014.01.009_bib0360","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2014.01.009_bib0365","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2014.01.009_bib0370","article-title":"A phase 3 study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis (MUSASHI)","author":"Ogata","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.smim.2014.01.009_bib0375","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1759720X12455960","article-title":"Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis","volume":"4","author":"Yokota","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.smim.2014.01.009_bib0380","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMe1212640","article-title":"A new era in the treatment of systemic juvenile idiopathic arthritis","volume":"367","author":"Sandborg","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2014.01.009_bib0385","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1172\/JCI114749","article-title":"Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice","volume":"86","author":"Brandt","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.smim.2014.01.009_bib0390","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199403033300904","article-title":"Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody","volume":"330","author":"Beck","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2014.01.009_bib0395","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2014.01.009_bib0400","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2014.01.009_bib0405","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/BOR.0b013e32835b133a","article-title":"New treatment strategies in large-vessel vasculitis","volume":"25","author":"Unizony","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.smim.2014.01.009_bib0410","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(12)60680-1","article-title":"Polymyalgia rheumatica","volume":"381","author":"Kermani","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2014.01.009_bib0415","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/ard.2008.099267","article-title":"Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment","volume":"68","author":"Nishida","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2014.01.009_bib0420","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ncl.2012.09.010","article-title":"Neuromyelitis optica: clinical manifestations and neuroimaging features","volume":"31","author":"Sahraian","year":"2013","journal-title":"Neurol Clin"},{"key":"10.1016\/j.smim.2014.01.009_bib0425","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.smim.2014.01.009_bib0430","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.berh.2008.08.006","article-title":"Adult-onset Still disease","volume":"22","author":"Fautrel","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.smim.2014.01.009_bib0435","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cell.2008.02.043","article-title":"Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury","volume":"133","author":"Imai","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.smim.2014.01.009_bib0440","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2014.01.009_bib0445","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.smim.2014.01.009_bib0450","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.7150\/ijbs.4666","article-title":"Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases","volume":"8","author":"Tanaka","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.smim.2014.01.009_bib0455","first-page":"S4-002","article-title":"Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update","author":"Tanaka","year":"2013","journal-title":"Rheumatol Curr Res"},{"key":"10.1016\/j.smim.2014.01.009_bib0460","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.25053","volume":"62","author":"Garnero","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2014.01.009_bib0465","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","article-title":"Brief report: inhibition of interleukin-6 function corrects Th17\/Treg cell imbalance in patients with rheumatoid arthritis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2014.01.009_bib0470","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/cei.12017","article-title":"Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients","volume":"171","author":"Pesce","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.smim.2014.01.009_bib0475","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7150\/ijbs.5996","article-title":"Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis","volume":"9","author":"Carbone","year":"2013","journal-title":"Int J Biol Sci"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532314000104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532314000104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T17:32:25Z","timestamp":1689010345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532314000104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1044532314000104"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2014.01.009","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726672831.793577021","asserted-by":"object"}]},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2014.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}